Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy

Nick Lagast; Charlotte Carlier; Wim P Ceelen

doi:10.1016/j.soc.2018.02.003

Pharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy

Surg Oncol Clin N Am. 2018 Jul;27(3):477-494. doi: 10.1016/j.soc.2018.02.003.

Authors

Nick Lagast¹, Charlotte Carlier¹, Wim P Ceelen²

Affiliations

¹ Department of Surgery, Ghent University, Cancer Research Institute Ghent (CRIG), Ghent B-9000, Belgium.
² Department of Surgery, Ghent University, Cancer Research Institute Ghent (CRIG), Ghent B-9000, Belgium. Electronic address: Wim.ceelen@ugent.be.

PMID: 29935684
DOI: 10.1016/j.soc.2018.02.003

Abstract

The presence of a peritoneal barrier results in a pharmacokinetic advantage associated with intraperitoneal (IP) delivery of anticancer drugs. The anticancer efficacy of IP chemotherapy depends, however, on its ability to penetrate the tumor stroma. Tumor tissue transport is governed by diffusion and convection and is affected by numerous physical, biological, and pharmaceutical variables. From preclinical and clinical studies, it appears that tissue penetration after IP chemotherapy delivery is very limited. Several approaches are studied in order to improve tissue penetration of small molecular and macromolecular anticancer drugs after IP instillation.

Keywords: Carcinomatosis; Chemotherapy; HIPEC; Pharmacokinetics.

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / pharmacokinetics*
Antineoplastic Agents / pharmacology
Humans
Injections, Intraperitoneal
Peritoneal Neoplasms / drug therapy*
Tissue Distribution

Substances

Antineoplastic Agents